Plasmonic and quantitative lateral flow assay for grayscale imaging of neutralizing antibodies SARS-CoV-2
作者
Karla R. Castro,Isabela A. Mattioli,Graziela Cristina Sedenho,Thiago Bertaglia,Antonio Fábio Medrado de Araújo,Manoel J.A. Lima,Beatriz G. R. da Silva,Mona N. Oliveira,Íris Todeschini,Phelipe Augusto Mariano Vitale,Erika R. Manuli,Geovana M. Pereira,Suzete C. Ferreira,Éster Cerdeira Sabino,Emanuel Carrilho,Frank N. Crespilho
出处
期刊:Talanta open [Elsevier BV] 日期:2025-06-14卷期号:12: 100504-100504被引量:3
Lateral flow immunoassays (LFIAs) have modernized decentralized mass testing and significantly impacted the healthcare system. It provides a rapid and accessible method for serological testing, which is an important tool for screening patients with past viral phases by detecting antibodies. Here, the development of a quantitative LFIA is presented, in which the receptor-binding domain of Spike protein-specific antibody (anti-S-RBD) in serum samples from previously infected with SARS-CoV-2 patients form an immune complex with the RBD protein immobilized on gold nanoparticles. For quantitative measurements, a methodology was developed based on the plasmonic behavior of gold nanoparticles and using a digital camera that processes images of the test lines in a closed chamber using the CYMK color system. The limits of detection and quantification were 0.22 and 0.70 µg mL –1 , respectively. The proposed device has a manufacturing cost of less than US$ 1 from synthesizing the bioconjugates, assembly of the LFIA strips, and 3D printing of the cassettes. The platform could detect anti-S-RBD antibodies in human serum samples and can be particularly useful in strategies for monitoring IgG levels in the population.